AHA To Put Aggressive BP Control In The Hot Seat For SPRINT-Excluded Groups

The American Heart Association’s 2026 Scientific Sessions are scheduled to feature two late-breaking trials of intensive blood pressure control in groups not included in the landmark SPRINT study: ischemic stroke survivors and higher-risk people with type 2 diabetes. The studies test a systolic blood pressure target below 120 mmHg, but results were not included in the report published ahead of the meeting.

The trials, named OPTIMAL-Stroke and OPTIMAL-Diabetes, are due to be presented on Saturday, November 7, according to MedPage Today’s preview of the meeting. Both enrolled people whose starting systolic blood pressure was between 130 and 180 mmHg and tested a target below 120 mmHg for cardiovascular protection.

The studies address distinct groups: OPTIMAL-Stroke focuses on people who have survived an ischemic stroke, while OPTIMAL-Diabetes focuses on higher-risk individuals with type 2 diabetes. The report describes both as groups excluded from SPRINT, whose findings helped shape changes to U.S. hypertension guidance in 2017.

The sessions are part of the AHA’s main scientific program, running November 7-9 in Chicago, with selected sessions livestreamed. Expanded programming began Friday, November 6. The preview identifies other cardiovascular topics on the agenda, but the two OPTIMAL trials are the meeting items directly testing intensive blood pressure control in these SPRINT-excluded populations.

Testing SPRINT’s Reach Beyond Its Participants

The trials matter because evidence supporting a lower blood pressure target may not apply equally to patient groups that were not represented in SPRINT. Studying people with prior ischemic stroke and those with higher-risk type 2 diabetes could help clarify whether an intensive target is appropriate for them, rather than relying on results from a different trial population.

That question has practical implications for clinicians weighing potential cardiovascular protection against the demands and risks of more intensive treatment. The meeting preview does not report trial outcomes, adverse events, or conclusions about changing care. Until those details are presented and assessed, the studies should be understood as evidence due to be reported—not as proof that a target below 120 mmHg benefits every patient in either group.

Products Worth Considering

OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG

AmazonView Latest Price

Withings BPM Connect Blood Pressure Monitor

AmazonView Latest Price

Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth

AmazonView Latest Price

As an affiliate, we earn on qualifying purchases.

How the Trials Relate to SPRINT

SPRINT was a landmark blood pressure trial whose findings contributed to the 2017 redefinition of hypertension in the United States, according to the MedPage Today report. It did not include the two populations now targeted by OPTIMAL-Stroke and OPTIMAL-Diabetes, leaving uncertainty about how its findings apply to them.

The new studies examine a similar intensive systolic target but in different patient groups. The source describes the work as addressing gaps left by SPRINT; it does not provide detailed trial methods, enrollment totals, follow-up periods, or the exact outcomes to be reported. Those details are needed to judge how closely the studies can inform treatment decisions.

“The OPTIMAL studies are expected to fill major gaps left by the landmark SPRINT trial.”

— Nicole Lou, MedPage Today senior staff writer

Trial Results and Treatment Implications

The source report was published before the scheduled presentations and does not give results from either trial. It is not yet clear from the preview whether the studies met their primary endpoints, how benefits and harms compared between treatment strategies, or whether findings differed among participants.

The report also does not state the number of participants, follow-up duration, treatment protocols beyond the systolic target, or whether results will support a change to clinical guidance. The presentations may provide these details, but no conclusions should be inferred from the trial names or planned targets alone.

Saturday Presentations and Data

OPTIMAL-Stroke and OPTIMAL-Diabetes are scheduled for the AHA’s late-breaking sessions on Saturday, November 7. The next key development is the presentation of trial findings, including the outcomes measured, the size and duration of each study, and the balance of cardiovascular benefits and potential harms.

After the sessions, clinicians and guideline groups will need to consider the full data and how it applies to patients outside the trials. The source preview does not specify when formal publications or any guidance updates may follow. The meeting runs through Monday, November 9, with selected sessions available by livestream.

Key Questions

What are OPTIMAL-Stroke and OPTIMAL-Diabetes?

They are two trials scheduled for presentation at the 2026 AHA meeting. One studies intensive blood pressure control in ischemic stroke survivors; the other studies higher-risk people with type 2 diabetes.

What blood pressure target are the trials testing?

Both trials test a systolic blood pressure target below 120 mmHg among participants whose starting systolic pressure was reported as 130-180 mmHg.

Why were these groups not covered by SPRINT?

The MedPage Today preview says people with prior ischemic stroke and the higher-risk type 2 diabetes group studied in OPTIMAL were excluded from SPRINT. The new trials are intended to address evidence gaps for those populations.

Do the trials show that intensive blood pressure control works?

The source preview does not report trial results. Findings and their implications remain unknown until the studies are presented and their data assessed.

Source: medpagetoday.com